A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

170

Participants

Timeline

Start Date

March 28, 2018

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2025

Conditions
Cardiovascular DiseasesType 2 Diabetes Mellitus
Interventions
DRUG

Apelin

Apelin is an endogenous peptide that activate a single G-protein couple receptor. Apelin inhibits insulin secretion, decreases glucose levels and increases insulin sensitivity.

DRUG

Relaxin

Relaxin is RLN2 encoded endogenous peptide hormone, which binds to G protein coupled receptor RXFP1.

DRUG

Normal saline

Vehicle

DIAGNOSTIC_TEST

Verapamil

NO independent challenge agent

DIAGNOSTIC_TEST

LN Monomethyl arginine

Basal NO synthase inhibitor

Trial Locations (1)

CB20QQ

Addenbrooke's Hospital, Cambridge

Sponsors

Collaborators (2)

All Listed Sponsors
collaborator

University of Cambridge

OTHER

collaborator

AstraZeneca

INDUSTRY

collaborator

MedImmune LLC

INDUSTRY

lead

Cambridge University Hospitals NHS Foundation Trust

OTHER